Oncology Pharma, Inc. Has Submitted Its Initial Application to List the Company on the Capital Markets Tier of the NASDAQ Exchange

Rhea-AI Summary

Oncology Pharma Inc. (OTC PINK:ONPH) has submitted its initial application to list on the Capital Markets Tier of the NASDAQ Exchange, indicating a strategic shift from the Pink Sheets. The company aims to expedite this transition using all available resources. With a focus on oncology therapeutics development, Oncology Pharma boasts a world-class Advisory Board. However, the company acknowledges risks related to operational cash flow, potential funding dilution, and regulatory challenges, which may affect its business outlook.

Positive

• Submitted initial application for NASDAQ listing, indicating growth strategy.
• Aims to utilize all resources to expedite the listing process.

Negative

• Current negative operating cash flows indicate financial instability.
• Need for additional funding may lead to highly dilutive terms.

SAN FRANCISCO, CA / ACCESSWIRE / May 12, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the "Company") has submitted its initial application to the NASDAQ to begin the process of moving the listing from the Pink Sheets to the Capital Markets Tier of the NASDAQ Exchange. The Company, its Board, advisors and management team are going to devote resources to accomplish this as swiftly as possible. We are delighted to have submitted the initial application and will work through the process utilizing all resources to our disposal.

ABOUT ONCOLOGY PHARMA, INC.

ONCOLOGY PHARMA, INC. (OTC PINK:ONPH) (the "Company") is currently engaging in research and development of therapeutics for oncology and prides itself for having a world-class Advisory Board that keeps the Company in the forefront of developing technologies in cancer research, biotechnology, and healthcare.

FORWARD LOOKING STATEMENTS

Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include risks related to licensing arrangements and joint ventures, including the need to negotiate the definitive agreements for the relationships; possible failure to realize anticipated benefits of business relationships; and costs of providing funding to these business relationships. Other risks and uncertainties relating to the Company include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners and with any strategic or joint venture partners; the impact of competition; the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; management of growth; and, other risks and uncertainties. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company's financial position.

CONTACTS:

For additional Information, please contact the Oncology Pharma at:
One Sansome Street, Suite 3500
San Francisco, CA 94104
Phone: 415-869-1038
Fax: 415-946-8801
website: www.oncology-pharma.com
email: info@oncology-pharma.com

SOURCE: Oncology Pharma Inc.

View source version on accesswire.com:
https://www.accesswire.com/647147/Oncology-Pharma-Inc-Has-Submitted-Its-Initial-Application-to-List-the-Company-on-the-Capital-Markets-Tier-of-the-NASDAQ-Exchange

FAQ

What is Oncology Pharma's recent development regarding NASDAQ listing?

Oncology Pharma has submitted its initial application to list on the Capital Markets Tier of NASDAQ, transitioning from the Pink Sheets.

How does the NASDAQ application impact Oncology Pharma's future?

The application may enhance visibility and credibility, but the company faces financial risks during this transition.

What are the risks mentioned in Oncology Pharma's press release?

Risks include negative operating cash flows, potential funding dilution, regulatory challenges, and overall market acceptance.

What is the stock symbol for Oncology Pharma?

The stock symbol for Oncology Pharma is ONPH.